eSOMA-DM1,一种基于梅坦类胺的疗效小分子药物结合剂,用于神经内分泌瘤
Dylan Chapeau1,2, Savanne Beekman1,2, Amber Piet1,2
1Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 GD, the Netherlands.
Bioconjugate chemistry
|October 12, 2024
概括
这项研究开发了eSOMA-DM1,一种用于神经内分泌瘤 (NETs) 的小分子药物联合体 (SMDC). 虽然在体外有希望,但体内研究表明需要优化eSOMA-DM1的分布,以改善治疗结果.
科学领域:
- 在瘤学瘤学.
- 放射化学 放射化学是指辐射化学.
- 分子生物学分子生物学
背景情况:
- 传统化疗面临选择性和副作用的挑战.
- 小分子药物联合体 (SMDCs) 提供细胞毒性剂的向输送.
- 神经内分泌瘤 (NETs) 表达体静止素受体亚型2 (SSTR2),是一种潜在的治疗标.
研究的目的:
- 设计和评估eSOMA-DM1,一个针对SSTR2的SMDC用于NET处理.
- 评估eSOMA-DM1的体外和体内特征,包括结合,吸收和生物分布.
- 探索双功能酸盐在同时诊断和治疗中的潜力.
主要方法:
- 合成eSOMA-DM1通过通过合SSTR2向性八酸和细胞毒剂DM1通过酸盐桥接链接器.
- 用印度-111 ([111In]) 给eSOMA-DM1进行放射性标记,用于成像和生物分布研究.
- 使用SSTR2转移细胞的体外试验和在瘤携带小鼠的体内研究.
主要成果:
- eSOMA-DM1与DOTA-TATE具有可比的SSTR2结合亲和力.
- [111In]In-eSOMA-DM1在体内显示出有前途的瘤吸收率,超过[111In]In-DOTA-TATE的吸收率.
- 长时间的[111In]In-eSOMA-DM1循环导致其在高度血管化的组织中积累,这表明需要药理动力学优化.
结论:
- eSOMA-DM1是具有良好的体外特征的NET的有前途的SMDC.
- 在体内生物分布需要调整以提高治疗效果.
- 需要进一步开发以优化eSOMA-DM1的分布形状,以便用于NET处理.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...